Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ramipril

FDA-approved product (capsule, oral), marketed as Altace, Ramipril, Vostally.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Ramipril
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acute myocardial infarction
  • Cardiovascular disease
  • Congestive heart failure
  • Coronary artery disease
  • Diabetes mellitus
  • Heart failure
  • Hypertension
  • Myocardial infarction
  • Stroke

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Ace inhibitors, plain
FDA pharmacologic class
Angiotensin Converting Enzyme Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA38.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli27.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae18.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ramipril in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ramipril with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN

    NCT00274599 · start 2002-10-09

    Registered record
    Registry ID
    NCT00274599
    Conditions
    Hypertension
    Interventions
    Telmisartan; Ramipril
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-10-09
    Completion
    Not recorded
    Enrolment
    812

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionTelmisartan; Ramipril
    PhasePhase 4
    Registry statusCompleted

  • To Investigate the Effect of Rosiglitazone and Ramipril on Pre-clinical Vasculopathy in Diabetes and IGT Patients

    NCT00489229 · start 2002-10

    Registered record
    Registry ID
    NCT00489229
    Conditions
    Diabetes; Impaired Glucose Tolerance
    Interventions
    Rosiglitazone; Ramipril
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-10
    Completion
    2005-12
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes; Impaired Glucose Tolerance
    InterventionRosiglitazone; Ramipril
    PhasePhase 3
    Registry statusCompleted

  • Treatment of Pediatric Hypertension With Altace Trial

    NCT00044265 · start 2002-07

    Registered record
    Registry ID
    NCT00044265
    Conditions
    Hypertension
    Interventions
    ramipril
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-07
    Completion
    2004-11
    Enrolment
    310

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventionramipril
    PhasePhase 4
    Registry statusCompleted

  • HYZAAR vs. Ramipril for Diabetes (0954A-245)(COMPLETED)

    NCT00480805 · start 2001-08-08

    Registered record
    Registry ID
    NCT00480805
    Conditions
    Type 2 Diabetes Mellitus; Hypertension
    Interventions
    MK0954A, losartan potassium (+) hydrochlorothiazide (HYZAAR) / Duration of Treatment : 8 Weeks; Comparator : ramipril /Duration of Treatment : 8 Weeks
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-08-08
    Completion
    2002-10-16
    Enrolment
    312

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus; Hypertension
    InterventionMK0954A, losartan potassium (+) hydrochlorothiazide (HYZAAR) / Duration of Treatment : 8 Weeks; Comparator : ramipril /Duration of Treatment : 8 Weeks
    PhasePhase 3
    Registry statusCompleted

  • Effects of Angiotensin-Converting Enzyme Inhibitor (Ramipril) Therapy on Blood Vessel Inflammation

    NCT00005928 · start 2000-06

    Registered record
    Registry ID
    NCT00005928
    Conditions
    Atherosclerosis; Coronary Disease; Vasculitis
    Interventions
    Ramipril
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2000-06
    Completion
    2002-02
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtherosclerosis; Coronary Disease; Vasculitis
    InterventionRamipril
    PhasePhase 2
    Registry statusCompleted